Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India.
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Curr Probl Cardiol. 2024 Feb;49(2):102237. doi: 10.1016/j.cpcardiol.2023.102237. Epub 2023 Nov 30.
Chronic total occlusion (CTO) is defined as a near-total blockage of a coronary artery and often occurs in arteries that are not directly responsible for the event, known as non-infarct-related arteries (NIRA). Cardiogenic shock (CS) is a complication of ST-elevated myocardial infarction (STEMI) that carries significant mortality. We performed a meta-analysis to find an association between mortality in patients undergoing PCI for STEMI that have superimposed CS, with the presence of CTO in the NIRA.
A comprehensive literature search was conducted using PubMed, EMBASE, Google Scholar and clinicaltrials.gov from inception till October 2023 to retrieve studies that compare the presence of CTO with the absence of CTO in NIRA in STEMI with CS patients undergoing PCI. The primary endpoint was 30-day mortality and the secondary endpoints were risk of all-cause mortality (ACM) and repeat myocardial infarction (MI). Forest plots were generated using the random effects model by pooling odds ratios (ORs) with a 95 % confidence interval. Statistical significance was set at p < 0.05.
5 observational studies with a total of 5186 patients (1031 with CTO in NIRA and 4155 with no CTO in NIRA) were included. The presence of CTO in NIRA was associated with higher odds of 30-day mortality [OR: 3.10; 95 % CI: 1.52, 6.32; p < 0.002], and ACM [OR: 2.37; 95 % CI: 1.83, 3.08; p < 0.00001]. The odds of repeat MI were comparable between the two groups [OR: 1.61, 95 % CI: 0.03, 74.36, p = 0.81].
The presence of CTO in the NIRA serves as an independent indicator of unfavorable clinical outcomes including increased risk of 30-day mortality and all-cause mortality. The risk of repeat MI was comparable between the two groups. Large-scale, multicenter trials are warranted to identify the most effective management approach for these patients.
慢性完全闭塞(CTO)定义为冠状动脉的近乎完全阻塞,通常发生在与事件无关的动脉中,称为非梗死相关动脉(NIRA)。心源性休克(CS)是 ST 段抬高型心肌梗死(STEMI)的并发症,死亡率很高。我们进行了一项荟萃分析,以确定在接受 PCI 治疗 STEMI 且合并 CS 的患者中,NIRA 中 CTO 的存在与死亡率之间的关联。
从开始到 2023 年 10 月,我们使用 PubMed、EMBASE、Google Scholar 和 clinicaltrials.gov 进行了全面的文献检索,以检索比较 STEMI 合并 CS 患者 PCI 中 NIRA 中 CTO 与无 CTO 存在的研究。主要终点是 30 天死亡率,次要终点是全因死亡率(ACM)和再发心肌梗死(MI)的风险。使用随机效应模型生成森林图,通过合并优势比(OR)并使用 95%置信区间进行汇总。统计显著性设为 p<0.05。
共纳入 5 项观察性研究,总计 5186 例患者(NIRA 中有 1031 例 CTO,NIRA 中无 4155 例 CTO)。NIRA 中 CTO 的存在与 30 天死亡率[OR:3.10;95%CI:1.52,6.32;p<0.002]和 ACM[OR:2.37;95%CI:1.83,3.08;p<0.00001]的增加显著相关。两组之间再发 MI 的可能性相当[OR:1.61,95%CI:0.03,74.36,p=0.81]。
NIRA 中的 CTO 是不利临床结局的独立指标,包括 30 天死亡率和全因死亡率增加的风险。两组之间再发 MI 的风险相当。需要进行大规模、多中心试验,以确定这些患者最有效的治疗方法。